EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 6019 participants.

Also called NCT05284747

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 6,019 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05284747
  • EudraCT 2021-005272-19
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, Sweden (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05284747. Randomized; no masking; primary purpose treatment. Start 2022-10-26 (actual); primary completion 2027-05-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Acronym
EVOLVE-MI
Condition
Cardiovascular Disease
Condition
Stroke
Condition
Coronary Revascularization
Intervention (Drug)
Evolocumab
Intervention (Drug)
Routine Lipid Management
Lead sponsor
Amgen (class: industry)
Collaborator
Colorado Prevention Center (class: other)

Record details

Record id
cardio:ct-nct05284747
Content hash
d0e206266deddf0edb4925383b09b4078006deb77bf48caa86d92c514d21055d